GSK‐3β inhibitors may reduce Aβ formation, inhibit tau protein hyperphosphorylation, participate in regulating other AD pathogenic mechanisms, reduce neuronal damage, and improve AD.17 Here, MAPT is linked to Alzheimer disease.